Untargeted metabolomic profiling of small extracellular vesicles reveals potential new biomarkers for triple negative breast cancer.

IF 3.5 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Metabolomics Pub Date : 2024-11-02 DOI:10.1007/s11306-024-02191-2

Rochelle D'Mello, Nico Hüttmann, Zoran Minic, Maxim V Berezovski

{"title":"Untargeted metabolomic profiling of small extracellular vesicles reveals potential new biomarkers for triple negative breast cancer.","authors":"Rochelle D'Mello, Nico Hüttmann, Zoran Minic, Maxim V Berezovski","doi":"10.1007/s11306-024-02191-2","DOIUrl":null,"url":null,"abstract":"Introduction: Breast Cancer (BC) is one of the most diagnosed malignancies among women and the second leading cause of cancer related death in North America. Triple Negative BC (TNBC), one of the most severe subtypes of BC, is extremely aggressive and has a higher chance of occurrence in women under 50 years of age. Due to a lack of regular mammographic testing in women under 50, many individuals with TNBC are diagnosed late which can decrease their survival rate. Currently, liquid biopsy is being investigated as a potentially less-invasive alternative to traditional breast tissue biopsy, but this approach is not completely reliable. Blood contains extracellular vesicles (EVs), which carry biomolecular cargo and play a role in BC progression and metastasis. Examination of small EVs could potentially yield metabolite biomarkers for early BC diagnosis.Objective: We aim to study metabolites in small EVs to find biomarkers for BC diagnosis.Methods: In this work, an untargeted nano-LC MS/MS metabolomics approach was used to analyze metabolites from small EVs derived from metastatic MDA-MB-231 and compare it with a non-cancerous MCF10A cell line.Results: Two metabolites, LysoPC 22:6/0:0 and N-acetyl-L-Phenylalanine, unique to sEVs of MDA-MB-231, were identified, validated, and proposed as potential BC biomarkers.Conclusion: Metabolites from sEVs may be used for BC diagnosis.","PeriodicalId":18506,"journal":{"name":"Metabolomics","volume":"20 6","pages":"123"},"PeriodicalIF":3.5000,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11306-024-02191-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Breast Cancer (BC) is one of the most diagnosed malignancies among women and the second leading cause of cancer related death in North America. Triple Negative BC (TNBC), one of the most severe subtypes of BC, is extremely aggressive and has a higher chance of occurrence in women under 50 years of age. Due to a lack of regular mammographic testing in women under 50, many individuals with TNBC are diagnosed late which can decrease their survival rate. Currently, liquid biopsy is being investigated as a potentially less-invasive alternative to traditional breast tissue biopsy, but this approach is not completely reliable. Blood contains extracellular vesicles (EVs), which carry biomolecular cargo and play a role in BC progression and metastasis. Examination of small EVs could potentially yield metabolite biomarkers for early BC diagnosis.

Objective: We aim to study metabolites in small EVs to find biomarkers for BC diagnosis.

Methods: In this work, an untargeted nano-LC MS/MS metabolomics approach was used to analyze metabolites from small EVs derived from metastatic MDA-MB-231 and compare it with a non-cancerous MCF10A cell line.

Results: Two metabolites, LysoPC 22:6/0:0 and N-acetyl-L-Phenylalanine, unique to sEVs of MDA-MB-231, were identified, validated, and proposed as potential BC biomarkers.

Conclusion: Metabolites from sEVs may be used for BC diagnosis.

查看原文本刊更多论文

细胞外小囊泡的非靶向代谢组学分析揭示了三阴性乳腺癌的潜在新生物标记物。

导言：乳腺癌（BC）是女性中确诊率最高的恶性肿瘤之一，也是北美癌症相关死亡的第二大原因。三阴性乳腺癌（TNBC）是乳腺癌中最严重的亚型之一，具有极强的侵袭性，在 50 岁以下女性中的发病率较高。由于 50 岁以下女性缺乏定期的乳腺 X 射线检查，许多 TNBC 患者的诊断时间较晚，这可能会降低她们的存活率。目前，液体活检作为传统乳腺组织活检的一种潜在微创替代方法正在接受研究，但这种方法并不完全可靠。血液中含有细胞外囊泡 (EV)，它们携带生物分子货物，在乳腺癌的进展和转移中发挥着作用。对小EVs的研究有可能为早期诊断BC提供代谢物生物标志物：我们旨在研究小EVs中的代谢物，为诊断BC寻找生物标志物：在这项工作中，我们采用非靶向纳米液相色谱 MS/MS 代谢组学方法分析了转移性 MDA-MB-231 小 EVs 中的代谢物，并将其与非癌 MCF10A 细胞系进行了比较：结果：MDA-MB-231的sEVs中特有的两种代谢物LysoPC 22:6/0:0和N-乙酰-L-苯丙氨酸被鉴定、验证并被认为是潜在的BC生物标志物：结论：sEVs 中的代谢物可用于 BC 诊断。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Metabolomics 医学-内分泌学与代谢

CiteScore

6.60

自引率

2.80%

发文量

审稿时长

2 months

期刊介绍： Metabolomics publishes current research regarding the development of technology platforms for metabolomics. This includes, but is not limited to: metabolomic applications within man, including pre-clinical and clinical pharmacometabolomics for precision medicine metabolic profiling and fingerprinting metabolite target analysis metabolomic applications within animals, plants and microbes transcriptomics and proteomics in systems biology Metabolomics is an indispensable platform for researchers using new post-genomics approaches, to discover networks and interactions between metabolites, pharmaceuticals, SNPs, proteins and more. Its articles go beyond the genome and metabolome, by including original clinical study material together with big data from new emerging technologies.